The incidence and prevalence of neuromyelitis optica

International Journal of MS Care

Volumn 15, Issue 3, 2013, Pages 113-119

  Marrie, Ruth Ann ^a   Gryba, Caroline ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84888384655     PISSN: 15372073     EISSN: None     Source Type: Journal    
DOI: 10.7224/1537-2073.2012-048     Document Type: Article

References (35)

1. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485-1489.
2. Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006;63:390-396.
3. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106-2112.
4. Kira J. Neuromyelitis optica and Asian phenotype of multiple sclerosis. Ann N Y Acad Sci. 2008;1142:58-71.
5. Cree BA, Khan O, Bourdette D, et al. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004;63:2039-2045.
6. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69:1176-1180.
7. Evans C, Beland S, Kulaga S, et al. Incidence and prevalence of multiple sclerosis in the Americas: a systematic review. Neuroepidemiology. 2013;40:195-210.
8. Boyle MH. Guidelines for evaluating prevalence studies. Evidence Based Mental Health. 1998;1:37-39.
9. NeyeloffJ, Fuchs S, Moreira L. Meta-analyses and Forest plots using a Microsoft Excel spreadsheet: step-by-step guide focusing on descriptivedata analysis. BMC Res Notes. 2012;5:52.
10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
11. Poppe AY, Wolfson C, Zhu B. Prevalence of multiple sclerosis in Canada: a systematic review. Can J Neurol Sci. 2008;35:593-601.
12. Asgari N, Lillevang ST, Skejoe HP, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589-1595.
13. Cabre P. Migration and multiple sclerosis: the French West Indies experience. J Neurol Sci. 2007;262:117-121.
14. Cabre P. Environmental changes and epidemiology of multiple sclerosis in the French West Indies. J Neurol Sci. 2009;286:58-61.
15. Cabre P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain. 2005;128:2899-2910.
16. Cabrera-Gomez JA, Kurtzke JF, Gonzalez-Quevedo A, Lara-Rodriguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009;256:35-44.
17. Cabre P, Heinzlef O, Merle H, et al. MS and neuromyelitis optica in Martinique (French West Indies). Neurology. 2001;56:507-514.
18. Cossburn M, Tackley G, Baker K, et al. The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol. 2012;19:655-659.
19. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999;53:1107.
20. McKee S, McNaughton F. Neuromyelitis optica: a report of two cases. Trans Am Ophthalmol Soc. 1937;35:125-135.
21. Kuroiwa Y, Igata A, Itahara K, et al. Nationwide survey of multiple sclerosis in Japan: clinical analysis of 1,084 cases. Neurology. 1975;25:845.
22. Bizzoco E, Lolli F, Repice AM, et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol. 2009;256:1891-1898.
23. Rivera J, Kurtzke J, Booth V, Corona T. Characteristics of Devic's disease (neuromyelitis optica) in Mexico. J Neurol. 2008;255:710-715.
24. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg. 2002;104:182-191.
25. Cocco E, Sardu C, Massa R, et al. Epidemiology of multiple sclerosis in south-western Sardinia. Mult Scler J. 2011;17:1282-1289.
26. McGuigan C, McCarthy A, Quigley C, Bannan L, Hawkins SA, Hutchinson M. Latitudinal variation in the prevalence of multiple sclerosis in Ireland, an effect of genetic diversity. J Neurol Neurosurg Psychiatry. 2003;75:572-576.
27. Bergamaschi R, Montomoli C, Candeloro E, et al. Bayesian mapping of multiple sclerosis prevalence in the province of Pavia, northern Italy. J Neurol Sci. 2006;244:127-131.
28. Modi G, Mochan A, Modi M, Saffer D. Demyelinating disorder of the central nervous system occurring in black South Africans. J Neurol Neurosurg Psychiatry. 2001;70:500-505.
29. Mirsattari SM, Johnston JB, McKenna R, et al. Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology. 2001;56:317-323.
30. Bamshad M. Genetic influences on health: does race matter? JAMA. 2005;294:937-946.
31. Collongues N, Marignier R, Zephir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology. 2010;74:736-742
32. Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J Neurol. 2004;251:47-52.
33. Wingerchuk DM. Neuromyelitis optica: effect of gender. J Neurol Sci. 2009;286:18-23.
34. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology. 2008;71:129-135.
35. Marrie RA, Yu N, Blanchard JF, Leung S, Elliott L. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology. 2010;74:465-471.